Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy

Ibrutinib is highly active and produces long-term responses in patients with Waldenström macroglobulinemia (WM), but acquired resistance can occur with prolonged treatment. We therefore evaluated the natural history and treatment outcomes in 51 WM patients with acquired resistance to ibrutinib monot...

Descripción completa

Detalles Bibliográficos
Autores principales: Gustine, Joshua N., Sarosiek, Shayna, Flynn, Catherine A., Meid, Kirsten, Leventoff, Carly, White, Timothy, Guerrera, Maria Luisa, Xu, Lian, Kofides, Amanda, Tsakmaklis, Nicholas, Munshi, Manit, Demos, Maria, Patterson, Christopher J., Liu, Xia, Yang, Guang, Hunter, Zachary R., Branagan, Andrew R., Treon, Steven P., Castillo, Jorge J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052900/
https://www.ncbi.nlm.nih.gov/pubmed/34162182
http://dx.doi.org/10.3324/haematol.2021.279112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052900/
https://www.ncbi.nlm.nih.gov/pubmed/34162182
http://dx.doi.org/10.3324/haematol.2021.279112

Ejemplares similares